CA2296314A1 - Amines cycliques modulant l'activite des recepteurs de chimiokines - Google Patents
Amines cycliques modulant l'activite des recepteurs de chimiokines Download PDFInfo
- Publication number
- CA2296314A1 CA2296314A1 CA002296314A CA2296314A CA2296314A1 CA 2296314 A1 CA2296314 A1 CA 2296314A1 CA 002296314 A CA002296314 A CA 002296314A CA 2296314 A CA2296314 A CA 2296314A CA 2296314 A1 CA2296314 A1 CA 2296314A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- methylbenzenesulfonamide
- alkyl
- substituted
- phenylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FBZWFIHRMVGCRB-UHFFFAOYSA-N CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)S(c1ccc(C)cc1)(=O)=O Chemical compound CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)S(c1ccc(C)cc1)(=O)=O FBZWFIHRMVGCRB-UHFFFAOYSA-N 0.000 description 2
- JHJAFOITADMHCO-UHFFFAOYSA-N CC(C)(C)CN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O Chemical compound CC(C)(C)CN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O JHJAFOITADMHCO-UHFFFAOYSA-N 0.000 description 1
- DPQVMNGLZUAFGN-UHFFFAOYSA-N CC(C)CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O Chemical compound CC(C)CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O DPQVMNGLZUAFGN-UHFFFAOYSA-N 0.000 description 1
- PEUMENXYAMVAGW-UHFFFAOYSA-N CC(C)CN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O Chemical compound CC(C)CN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OCc1ccccc1)=O PEUMENXYAMVAGW-UHFFFAOYSA-N 0.000 description 1
- LBLYISNPJJQQNN-UHFFFAOYSA-N CCCCCCCCS(N(CC)C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)(=O)=O Chemical compound CCCCCCCCS(N(CC)C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)(=O)=O LBLYISNPJJQQNN-UHFFFAOYSA-N 0.000 description 1
- UBUCJAURBOXTIN-UHFFFAOYSA-N CCCCCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OC)=O Chemical compound CCCCCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)C(OC)=O UBUCJAURBOXTIN-UHFFFAOYSA-N 0.000 description 1
- IYBLEBKJAGGLEF-UHFFFAOYSA-N CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)S(C(C=C1)=CCC1(C)Cl)(=O)=O Chemical compound CCN(C1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1)S(C(C=C1)=CCC1(C)Cl)(=O)=O IYBLEBKJAGGLEF-UHFFFAOYSA-N 0.000 description 1
- FFEDCHGHDYQTEH-UHFFFAOYSA-N CCNC1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1 Chemical compound CCNC1CCN(CCC(CN(C)S(c2ccccc2)(=O)=O)c2ccccc2)CC1 FFEDCHGHDYQTEH-UHFFFAOYSA-N 0.000 description 1
- PSTIIJCELPEDNW-UHFFFAOYSA-N CN(CC(CCN(CC1)CCC1N(CC1CC1)C(OC)=O)c1ccccc1)S(c1ccccc1)(=O)=O Chemical compound CN(CC(CCN(CC1)CCC1N(CC1CC1)C(OC)=O)c1ccccc1)S(c1ccccc1)(=O)=O PSTIIJCELPEDNW-UHFFFAOYSA-N 0.000 description 1
- VHBRZABEWHYCMY-UHFFFAOYSA-N CN(CC(CCN(CC1)CCC1c1ccccc1)Cc1ccccc1)S(c1ccccc1)(=O)=O Chemical compound CN(CC(CCN(CC1)CCC1c1ccccc1)Cc1ccccc1)S(c1ccccc1)(=O)=O VHBRZABEWHYCMY-UHFFFAOYSA-N 0.000 description 1
- DZNWWHDJWHTPPT-UHFFFAOYSA-N CN(CC(CCN(CC1)CCC1c1ccccc1)c1cc(cccc2)c2cc1)S(c1ccccc1)(=O)=O Chemical compound CN(CC(CCN(CC1)CCC1c1ccccc1)c1cc(cccc2)c2cc1)S(c1ccccc1)(=O)=O DZNWWHDJWHTPPT-UHFFFAOYSA-N 0.000 description 1
- VSOMMAPLZXHECG-UHFFFAOYSA-N Cc1c(C2CCN(CCC(CN(C)S(C)(c3ccccc3)(O)=O)c3ccccc3)CC2)cccc1 Chemical compound Cc1c(C2CCN(CCC(CN(C)S(C)(c3ccccc3)(O)=O)c3ccccc3)CC2)cccc1 VSOMMAPLZXHECG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention se rapporte à des amines cycliques représentées par la formule (I), dans laquelle R?1¿, R?2¿, R?3¿, m et n sont définis dans le descriptif de l'invention. Ces amines s'avèrent utiles en tant que modulateurs de l'activité des récepteurs de chimiokines, et notamment des récepteurs CCR-1, CCR-2, CCR2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3 et/ou CXCR-4.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5375497P | 1997-07-25 | 1997-07-25 | |
US60/053,754 | 1997-07-25 | ||
GB9800958.2 | 1998-01-16 | ||
GBGB9800958.2A GB9800958D0 (en) | 1998-01-16 | 1998-01-16 | Cyclic amine modulators of chemokine activity |
PCT/US1998/014990 WO1999004794A1 (fr) | 1997-07-25 | 1998-07-21 | Amines cycliques modulant l'activite des recepteurs de chimiokines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2296314A1 true CA2296314A1 (fr) | 1999-02-04 |
Family
ID=26312958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296314A Abandoned CA2296314A1 (fr) | 1997-07-25 | 1998-07-21 | Amines cycliques modulant l'activite des recepteurs de chimiokines |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1003514A4 (fr) |
JP (1) | JP2002510327A (fr) |
AU (1) | AU8576098A (fr) |
CA (1) | CA2296314A1 (fr) |
WO (1) | WO1999004794A1 (fr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
PT1131291E (pt) * | 1998-11-17 | 2005-01-31 | Hoffmann La Roche | Antagonistas iii do receptor 4-aroil-piperidin-ccr-3 |
AU2056800A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
CA2348923A1 (fr) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines |
WO2000035453A1 (fr) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines |
US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
EP1013276A1 (fr) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalcanes comme modulateurs de CCR5 |
PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
TR200102799T2 (tr) * | 1999-03-24 | 2002-07-22 | Anormed Inc. | Kemokin alıcı bağlayıcı heterosiklik bileşikler |
AU4143300A (en) * | 1999-04-28 | 2000-11-17 | Takeda Chemical Industries Ltd. | Cyclic amide compounds, process for the preparation of the same and uses thereof |
US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6689765B2 (en) | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
PL203117B1 (pl) * | 1999-05-04 | 2009-08-31 | Schering Corp | Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
PL203116B1 (pl) * | 1999-05-04 | 2009-08-31 | Schering Corp | Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
EP1050307A1 (fr) * | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | Antagonistes de CCR4 contre la septicémie |
US6500844B1 (en) | 1999-06-11 | 2002-12-31 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
AU5328500A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | N-cyclopentyl modulators of chemokine receptor activity |
AU5473800A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
EP1192133B1 (fr) * | 1999-06-11 | 2006-11-02 | Merck & Co., Inc. | Modulateurs n-cyclopentyliques de l'activite du recepteur de la chimiokine |
US6538002B1 (en) | 1999-06-11 | 2003-03-25 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
US6432981B1 (en) | 1999-06-11 | 2002-08-13 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
US6358979B1 (en) | 1999-06-11 | 2002-03-19 | Merck & Co., Inc. | N-cyclopentyl modulators of chemokine receptor activity |
SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
PE20010628A1 (es) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
AU7556000A (en) | 1999-10-05 | 2001-05-10 | Takeda Chemical Industries Ltd. | Urea compounds, process for producing the same and use thereof |
GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US6667314B2 (en) | 2000-05-26 | 2003-12-23 | Pfizer, Inc. | Tropane derivatives useful in therapy |
KR100523501B1 (ko) * | 2000-05-26 | 2005-10-25 | 화이자 인코포레이티드 | Ccr5 조절제로서의 트리아졸릴 트로판 유도체 |
GB0013060D0 (en) * | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
MXPA02012712A (es) | 2000-06-30 | 2003-04-25 | Bristol Myers Squibb Pharma Co | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. |
TWI227231B (en) * | 2000-07-12 | 2005-02-01 | Novartis Ag | 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3 |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
AU2002230665A1 (en) | 2000-12-06 | 2002-06-18 | Sepracor, Inc. | 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
PE20020996A1 (es) | 2001-03-29 | 2002-11-01 | Schering Corp | Antagonistas de ccr5 utiles para el tratamiento del sida |
GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
US7307090B2 (en) | 2001-07-02 | 2007-12-11 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
AU2002326948A1 (en) | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
TW200305395A (en) * | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
WO2003084942A2 (fr) * | 2002-03-29 | 2003-10-16 | Schering Corporation | Alkylation stereoselective de piperazines 2-methyl-4-protegees chirales |
TW200409630A (en) | 2002-09-12 | 2004-06-16 | Bristol Myers Squibb Co | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
AU2003275257A1 (en) | 2002-09-26 | 2004-04-19 | Bristol-Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
JP2006511500A (ja) * | 2002-10-30 | 2006-04-06 | メルク エンド カムパニー インコーポレーテッド | γ−アミノアミド系のケモカイン受容体活性調節剤 |
CA2509711A1 (fr) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Antagonistes de ccr5 utiles comme agents therapeutiques |
EP1604981A4 (fr) * | 2003-03-14 | 2008-12-24 | Ono Pharmaceutical Co | Derives heterocycliques renfermant de l'azote et medicaments contenant ces derives comme principe actif |
JP5208412B2 (ja) | 2003-03-24 | 2013-06-12 | アクシキン ファーマシューティカルズ インコーポレーテッド | ベンゼンスルホンアミド誘導体 |
SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
JP4710606B2 (ja) | 2003-04-18 | 2011-06-29 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
RU2006100298A (ru) | 2003-06-11 | 2006-05-10 | Мерк энд Ко., Инк. (US) | Замещенные производные 3-алкил-и 3-алкенилазетидинов |
JP2007505080A (ja) * | 2003-09-15 | 2007-03-08 | ノバルティス アクチエンゲゼルシャフト | 炎症性およびアレルギー性疾患の処置における、ccr−3受容体アンタゴニストとして使用するための1,3−二置換アゼチジン誘導体 |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
RU2409565C2 (ru) | 2004-09-13 | 2011-01-20 | Оно Фармасьютикал Ко., Лтд. | Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
EP1889622A4 (fr) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | Compose de spiropiperidine et son utilisation medicinale |
WO2006138350A2 (fr) * | 2005-06-15 | 2006-12-28 | Anormed Inc. | Composes de liaison au recepteur de la chimiokine |
EP1912941B1 (fr) | 2005-07-21 | 2012-11-14 | AstraZeneca AB | Derives de piperidine |
EP1942108B1 (fr) | 2005-10-28 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Compose contenant un groupe basique et son utilisation |
PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
BRPI0708731A2 (pt) | 2006-03-10 | 2011-06-07 | Ono Pharmaceutical Co | derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
WO2008016006A1 (fr) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation |
WO2010129351A1 (fr) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge |
WO2011011652A1 (fr) | 2009-07-24 | 2011-01-27 | Glaxosmithkline Llc | Composés thérapeutiques |
EP2741777B1 (fr) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Procédés et compositions pharmaceutiques pour le traitement de l'hypertension pulmonaire |
WO2016100823A1 (fr) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Ligands du récepteur d2 de la dopamine |
US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017106328A1 (fr) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Méthodes de traitement du cancer |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
CA3027498A1 (fr) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Inhibiteurs de cxcr4 et leurs utilisations |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN110483490B (zh) * | 2019-08-29 | 2023-02-03 | 苏州汉德创宏生化科技有限公司 | 一种3-(哌啶-4-基)恶唑烷-2-酮及其盐的合成方法 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9100505D0 (en) * | 1991-01-10 | 1991-02-20 | Shell Int Research | Piperidine derivatives |
GB9321557D0 (en) * | 1992-11-03 | 1993-12-08 | Zeneca Ltd | Carboxamide derivatives |
GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
GB9502644D0 (en) * | 1995-02-10 | 1995-03-29 | Zeneca Ltd | Heterocyclic derivatives |
JP2000504677A (ja) * | 1996-02-09 | 2000-04-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht7レセプター・アンタゴニスト用のスルホンアミド誘導体 |
US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
-
1998
- 1998-07-21 WO PCT/US1998/014990 patent/WO1999004794A1/fr not_active Application Discontinuation
- 1998-07-21 AU AU85760/98A patent/AU8576098A/en not_active Abandoned
- 1998-07-21 JP JP50994999A patent/JP2002510327A/ja active Pending
- 1998-07-21 EP EP98936920A patent/EP1003514A4/fr not_active Withdrawn
- 1998-07-21 CA CA002296314A patent/CA2296314A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002510327A (ja) | 2002-04-02 |
AU8576098A (en) | 1999-02-16 |
WO1999004794A1 (fr) | 1999-02-04 |
EP1003514A1 (fr) | 2000-05-31 |
EP1003514A4 (fr) | 2000-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6136827A (en) | Cyclic amine modulations of chemokine receptor activity | |
CA2296314A1 (fr) | Amines cycliques modulant l'activite des recepteurs de chimiokines | |
US6166037A (en) | Pyrrolidine and piperidine modulators of chemokine receptor activity | |
US6140349A (en) | Cyclic amine modulators of chemokine receptor activity | |
WO1999038514A1 (fr) | Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine | |
US5962462A (en) | Spiro-substituted azacycles as modulators of chemokine receptor activity | |
CA2298813A1 (fr) | Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine | |
US6013644A (en) | Spiro-substituted azacycles as modulators of chemokine receptor activity | |
US6303593B1 (en) | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity | |
US6362201B1 (en) | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity | |
US6489354B1 (en) | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity | |
US6124319A (en) | 3,3-disubstituted piperidines as modulators of chemokine receptor activity | |
WO1998025617A1 (fr) | Arylpiperazines substituees utilisees comme modulateurs de l'activite du recepteur de la chemokine | |
US6432981B1 (en) | Cyclopentyl modulators of chemokine receptor activity | |
WO1998025604A1 (fr) | Azacycles a spiro-substitution utilises en tant que modulateurs de l'activite du recepteur de la chimiokine | |
WO1998025605A1 (fr) | Azacycles spiro-substitues utilises comme modulateurs de l'activite des recepteurs de la chemokine | |
US6372764B1 (en) | Pyrrolidine modulators of chemokine receptor activity | |
CA2278309A1 (fr) | Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines | |
US6506777B1 (en) | Cyclopentyl modulators of chemokine receptor activity | |
US6500844B1 (en) | Cyclopentyl modulators of chemokine receptor activity | |
US6472410B1 (en) | N-cyclopentyl modulators of chemokine receptor activity | |
US6538002B1 (en) | Cyclopentyl modulators of chemokine receptor activity | |
EP1192133B1 (fr) | Modulateurs n-cyclopentyliques de l'activite du recepteur de la chimiokine | |
US6455548B2 (en) | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |